Gangagen Secures Additional US$7.9 Million From CARB-X For Pre-Clinical Development Of Novel Klebicins Targeting Nosocomial Pneumonia Caused By Multidrug-Resistant Klebsiella Pneumoniae Media Outreach Newswire APAC

Published on December 23, 2024

announced today that it has secured the third instalment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria

Continue reading on website
Other news

NSPCC calls for new volunteers in 2025 - how to help

December 23, 2024
which relies largely on public donations to fund its services, needs volunteers to help organise fundraising events, to share its vital

Chesnara agrees second Canada Life portfolio acquisition in two years

December 23, 2024
provides an attractive return on investment for our shareholders". "We continue to see a range of M&A opportunities and are highly confident